Vestaron
Active#4 worldwide · Biological inputsDevelops peptide-based bioinsecticides derived from natural venom peptides, sold to growers as alternatives to synthetic insecticides for field and greenhouse crops.
Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Biological inputs · worldwide | Top 32 | #4 | Edition 0 · Oct 2026 | 12 Feb 2027 |
Estimated valuation
AI · Biological inputs ranking (worldwide)- Anchor
- Last known equity round: Series C · USD 92M · Aug 2022
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Funding history
| Date | Round | Amount | Type | Investors |
|---|---|---|---|---|
| Aug 2022 | Series C | USD 92M | Equity | Ordway Selections, Cavallo Ventures, Novo Holdings, Syngenta Ventures, Fortistar |
USD 82M plus a USD 10M extension.
Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Vestaron as a PDF. It must answer at least one of these four questions, and stick to them:
Analyses are the opinion of their authors, not of Uback. They are checked before publication.
Comparable companies in biological inputs
Full biological inputs ranking →Investors in Vestaron: Ordway Selections · Cavallo Ventures · Novo Holdings · Syngenta Ventures · Fortistar
Last updated: Oct 2026Report an error
Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.